Get started
Author

Kathleen J. Schostack

Observed names: K. Schostack, Kathleen Schostack
OpenAlex ID: A5017486169
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
2010 · Hong Yang, Brian Higgins, et al. · Cancer Research · 404
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
2011 · Hong Yang, Brian Higgins, et al. · Cancer Research · 216
PDF
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
2011 · Fei Su, William D. Bradley, et al. · Cancer Research · 178
Preferred set selection by iterative key set factor analysis
1989 · Kathleen J. Schostack, Edmund R. Malinowski · Chemometrics and Intelligent Laboratory Systems · 69
Investigation of window factor analysis and matrix regression analysis in chromatography
1993 · Kathleen J. Schostack, Edmund R. Malinowski · Chemometrics and Intelligent Laboratory Systems · 46
A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
2014 · Ulrik N. Lassen, Didier Meulendijks, et al. · Clinical Cancer Research · 43
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2013 · Xuefeng Yin, Leopoldo Luistro, et al. · Clinical Cancer Research · 41
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
2015 · Didier Meulendijks, Ulrik N. Lassen, et al. · Clinical Cancer Research · 23
Theory of evolutionary factor analysis for resolution of ternary mixtures
1990 · Kathleen J. Schostack, Edmund R. Malinowski · Chemometrics and Intelligent Laboratory Systems · 13
Theory of evolutionary factor analysis for resolution of quaternary-plus mixtures
1991 · Kathleen J. Schostack, Edmund R. Malinowski · Chemometrics and Intelligent Laboratory Systems · 9
Evolutionary factor-analysis
1988 · K. Schostack, P. Parekh, et al. · Journal of Research of the National Bureau of Standards · 7
PDF
Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
2012 · Brian Higgins, Kenneth Daniel Kolinsky, et al. · Journal of Clinical Oncology · 6
372 Preclinical Characterization of RG7256, a Potent and Selective BRAF Inhibitor with Differentiation From Vemurafenib
2012 · F. Su, L. Xu, et al. · European Journal of Cancer · 2
Pharmaceutical analysis documentation
2001 · Hitesh Chokshi, Kathleen Schostack · Separation science and technology · 2
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
2015 · Rodrigo Dienstmann, Ulrik Lassen, et al. · Targeted Oncology · 1
Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib
2015 · Heiko Krissel, Andrea Hennig, et al. · Cancer Research · 1
Pharmaceutical Analysis Documentation
2010 · Hitesh Chokshi, Kathleen Schostack, et al. · Separation science and technology · 1
Data from A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
2023 · Ulrik N. Lassen, Didier Meulendijks, et al.
Supplementary Table 1 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Supplementary Figure 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Supplementary Figure 1 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
PDF
Supplementary Table 2 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Supplementary Table 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Supplementary Figure 2 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Supplementary Figure Legends and Table Legends and Methods from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
2023 · Xuefeng Yin, Leopoldo Luistro, et al.
Works count: 62
Citation count: 1,062
H-index: 9
I10-index: 9
Year
Topic
Type